pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,216 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints891BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7582Rare Disease1868Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • Long Covid research faces funding cut as NIH terminates grant, highlighting political neglect
    Steven Phillips, a science strategist at the COVID Collaborative, notes that a two‑year study of long Covid’s impact on the nervous system was halted when the NIH withdrew its RECOVER grant, labeli…
    STAT · 2mo agoNegative↗ source
  • STAT+ podcast explores new obesity drugs, record IPO and FDA peptide access
    On June 11, 2026, STAT’s biotech podcast "The Readout Loud" released an episode that dives into the expanding field of obesity therapeutics. The hosts review several experimental obesity drugs tha…
    STAT · 2mo agoNeutral↗ source
← prev
page 67 of 89
next →
fda recalls69
fda medwatch60
fda press38
1171
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism473
Infectious Disease444
Abridge secures strategic investment from Eli Lilly and partners with Nvidia on AI foundation model
Abridge, a health‑tech AI company, announced two new deals on Thursday in New York. Eli Lilly will make a strategic investment in Abridge, signaling pharma interest in AI scribes that document vis…
STAT · 2mo agoDealPositive↗ source
  • Some U.S. Employers Plan to End GLP-1 Obesity Drug Coverage in 2027, Even as Prices Fall
    A Reuters report says roughly 10% of U.S. employers that currently cover GLP-1 medicines for weight loss intend to stop covering them in 2027. The move comes as enrollment in obesity-treating drugs…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • AMA and lawmakers challenge insurer AI denial practices, call for oversight
    The American Medical Association and several members of Congress are publicly opposing recent denials of care that rely on artificial‑intelligence algorithms used by insurers. The Department of He…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Nonprofit Blood Cancer United purchases remaining Luvelta supplies to keep compassionate access for children
    Blood Cancer United, formerly the Leukemia & Lymphoma Society, announced it will purchase the remaining inventory of Luvelta, an investigational antibody‑drug conjugate that had been discontinued.…
    STAT · 2mo agoDealPositive↗ source
  • Study finds socioeconomic status drives brain development differences in 9- and 10-year-olds
    Researchers at Washington University School of Medicine examined brain MRI scans from almost 12,000 children who were nine or ten years old. The analysis showed that a child's socioeconomic backgr…
    STAT · 2mo agoNeutral↗ source
  • Medicare Advantage insurers often reverse denied claims on appeal, sparking concerns over care barriers
    STAT's D.C. Diagnosis newsletter reports a troubling pattern in Medicare Advantage plans where initial claim denials are frequently reversed after an appeal. The analysis highlights that most large…
    STAT · 2mo agoRegulatoryNegative↗ source
  • CDC report finds rise in alcohol use among pregnant women since 2020
    A new CDC analysis shows that the proportion of pregnant adults who reported drinking in the past month increased after 2020. The survey data indicate that about 15% of pregnant women reported cur…
    STAT · 2mo agoNegative↗ source
  • Sensorion drops OTOF gene therapy to focus on GJB2-targeted hearing loss candidate after Regeneron approval
    Sensorion said it is ending development of its gene therapy SENS-501 for OTOF related hearing loss after a strategic review. The review concluded that the competitive landscape had changed signific…
    BioPharma Dive · 2mo agoNeutral↗ source
  • HHS gives measured response to alcohol risk study as health news roundup covers soda link, NIH debate, diabetes apology and DOJ lawsuit
    The Department of Health and Human Services issued a cautious reaction to a recent paper that examined the relationship between alcohol consumption and health risks, noting the need for further evi…
    STAT · 2mo agoNeutral↗ source
  • NIH mulls grant cap to broaden funding across universities
    NIH officials are evaluating a proposal that would limit the number of research grants any single investigator can receive. The goal is to spread federal funding more evenly across institutions. R…
    STAT · 2mo agoRegulatoryPositive↗ source
  • HHS Secretary RFK Jr. says his calendar is public, but STAT finds no record after a year of requests
    Health secretary Robert F. Kennedy Jr. told reporters his calendar is publicly available as proof of his “radical transparency” pledge. STAT has filed Freedom of Information Act requests and email…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Open-access fees rise to $12,850 for NIH-funded study in Nature Medicine
    In 2025 a randomized clinical trial led by Elizabeth Selvin was published in Nature Medicine without any publication charge. The paper underwent peer review and editorial processing at no cost to t…
    STAT · 2mo agoNegative↗ source
  • AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight loss
    AstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Parabilis raises record $670 million in biotech IPO, the largest for a venture-backed company
    Parabilis Medicines, a biotech focused on "undruggable" targets, completed an initial public offering that raised $670 million, the biggest amount ever for a venture-backed biotech. The company so…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Sanofi halts Phase 3 trial of riliprubart in CIDP after interim analysis shows unlikely efficacy
    Sanofi announced Wednesday that it is stopping the Phase 3 MOBILIZE study of its experimental anti‑inflammatory drug riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • US judge upholds law to curb hospital drug prices as shortage trends show mixed signals
    A federal judge in Washington rejected a pharmaceutical industry challenge to a state law aimed at lowering hospital drug prices, leaving the pricing reforms in place. Data from a recent analysis…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Europe’s drug pricing split: UK leans pro‑industry while Germany eyes cuts and higher fees
    European nations are feeling mounting pressure to rein in drug prices, a trend that is reshaping the market for both manufacturers and patients across the continent. In the United Kingdom, lobbyin…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Ethyreal Bio raises $101M to develop antibody targeting Graves disease and thyroid eye disease
    Ethyreal Bio, a Cambridge-based biotech that has just emerged from stealth mode, announced it has closed a $101 million financing round to advance its lead candidate. The company’s candidate, a mo…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Sanofi halts rare disease trial as Parabilis launches record biotech IPO amid European pricing debate
    Sanofi announced it is stopping a Phase 3 trial of its experimental drug riliprubart in a rare autoimmune disease after an interim analysis showed the treatment did not work. The pause adds to rec…
    STAT · 3mo agoNeutral↗ source
  • Republican pushback on methadone and buprenorphine raises concerns among addiction experts
    Recent guidance from the Trump administration has revived a debate over the use of methadone and buprenorphine for opioid addiction treatment, prompting renewed scrutiny of federal policy. Addicti…
    STAT · 3mo agoRegulatoryNegative↗ source
  • DOJ announces second settlement on youth gender-affirming care amid broader health news
    The Department of Justice disclosed that it has reached a second settlement with parties involved in providing gender-affirming care to minors. The agreement, announced in a recent newsletter, buil…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • ADA CEO apologizes for expelling five members over protest literature, vows review and trust rebuilding
    Five members of the American Diabetes Association were removed from its annual scientific sessions in New Orleans after distributing editorial material that criticized federal research funding cuts…
    STAT · 2mo agoNegative↗ source
  • ACOG issues new pregnancy vaccine schedule that diverges from CDC guidance
    The American College of Obstetricians and Gynecologists (ACOG) released a new vaccine schedule for pregnant individuals that differs from the current CDC guidance. ACOG recommends four vaccines be…
    STAT · 3mo agoNeutral↗ source